Clinical trial
Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in…
NCT00104065 · CuraGen Corporation, Industry · Completed
Key facts
| NCT number | NCT00104065 |
|---|---|
| Title | Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant |
| Official title | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant |
| Lead sponsor | CuraGen Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stomatitis |
| Intervention type | Drug |
| Interventions | CG53135-05, velafermin |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Feb 23, 2005 |
| Last update posted | Mar 15, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: